MacroGenics Inc. (MGNX) receives a Neutral rating from Guggenheim


In a filing, MacroGenics Inc. revealed its Director HURWITZ EDWARD acquired Company’s shares for reported $73650.0 on Aug 30. In the deal valued at $4.91 per share,15,000 shares were bought. As a result of this transaction, HURWITZ EDWARD now holds 33,074 shares worth roughly $ 0.16 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Peters Jeffrey Stuart sold 5,372 shares, generating $32,393 in total proceeds. Upon selling the shares at $6.03, the Senior VP and General Counsel now owns 0 shares.

Before that, BIOTECH TARGET N V bought 500,000 shares. MacroGenics Inc. shares valued at $2,532,600 were divested by the 10% Owner at a price of $5.07 per share. As a result of the transaction, BIOTECH TARGET N V now holds 9,579,963 shares, worth roughly $46.56 million.

Guggenheim downgraded its MacroGenics Inc. [MGNX] rating to a Neutral from a a Buy in a research note published on Friday.

Price Performance Review of MGNX

On Friday, MacroGenics Inc. [NASDAQ:MGNX] saw its stock jump 4.29% to $4.86. On the same session, the stock had its day’s lowest price of $4.71, but rose to a high of $4.88. Over the last five days, the stock has lost -3.76%. MacroGenics Inc. shares have fallen nearly -27.57% since the year began. Nevertheless, the stocks have risen 22.42% over the past one year. While a 52-week high of $7.90 was reached on 05/10/23, a 52-week low of $2.93 was recorded on 07/27/23. SMA at 50 days reached $5.08, while 200 days put it at $5.90. A total of 0.26 million shares were traded, compared to the trading of 0.34 million shares in the previous session.

Levels Of Support And Resistance For MGNX Stock

The 24-hour chart illustrates a support level at 4.75, which if violated will result in even more drops to 4.65. On the upside, there is a resistance level at 4.92. A further resistance level may holdings at 4.99. The Relative Strength Index (RSI) on the 14-day chart is 45.04, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.24, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 78.02%. Stochastics %K at 10.73% indicates the stock is a buying.

How much short interest is there in MacroGenics Inc.?

A steep rise in short interest was recorded in MacroGenics Inc. stocks on Aug 14, 2023, dropping by -0.71 million shares to a total of 5.01 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 5.72 million shares. There was a decline of -14.17%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 9.88% of the overall stock float, the days-to-cover ratio (short ratio) fell to 7.78.

MacroGenics Inc. [MGNX] – Who Are The Largest Shareholders?

In filings from Bellevue Asset Management AG, it is revealed that the company now owns 9,609,913 shares, or roughly 15.54% of the outstanding MGNX shares. Additionally, Armistice Capital LLC decreased -6.04% of its stake after which the total value it holdings stand at $26,712,000, while T. Rowe Price Investment Manageme added 87.50% of its stake to hold $26.06 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 20,599 shares of MacroGenics Inc., while The Vanguard Group, Inc. bought -115,709 shares. At present, Wasatch Advisors, Inc. is holding 1,409,050 shares valued at $6.72 million. SSgA Funds Management, Inc. owned 1,300,301 shares of the company at the time of its most recent 13F filing, worth $6.2 million.


Please enter your comment!
Please enter your name here